In vitro evaluation of a hybrid drug-delivery nanosystem for fibrosis prevention in cell therapy for Type 1 diabetes.

Rennie, C; Huang, Y; Siwakoti, P; Du, Z; Padula, M; Bao, G; Tuch, BE; Xu, X; McClements, L

In vitro evaluation of a hybrid drug-delivery nanosystem for fibrosis prevention in cell therapy for Type 1 diabetes.

Rennie, C

Huang, Y Siwakoti, P Du, Z Padula, M

Bao, G

Tuch, BE Xu, X

McClements, L

Permalink

Publisher:: FUTURE MEDICINE LTD
Publication Type:: Journal Article
Citation:: Nanomedicine (Lond), 2023, 18, (1), pp. 53-66
Issue Date:: 2023-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

The embargo period expires on 20 Mar 2024

Adobe PDF

Download Accepted versionAdobe PDF (1.7 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Rennie, C https://orcid.org/0000-0003-4533-6627
dc.contributor.author	Huang, Y
dc.contributor.author	Siwakoti, P
dc.contributor.author	Du, Z
dc.contributor.author	Padula, M https://orcid.org/0000-0002-8283-0643
dc.contributor.author	Bao, G https://orcid.org/0000-0001-5103-5009
dc.contributor.author	Tuch, BE
dc.contributor.author	Xu, X https://orcid.org/0000-0002-2598-3766
dc.contributor.author	McClements, L https://orcid.org/0000-0002-4911-1014
dc.date.accessioned	2024-03-07T23:42:13Z
dc.date.available	2024-03-07T23:42:13Z
dc.date.issued	2023-01
dc.identifier.citation	Nanomedicine (Lond), 2023, 18, (1), pp. 53-66
dc.identifier.issn	1743-5889
dc.identifier.issn	1748-6963
dc.identifier.uri	http://hdl.handle.net/10453/176319
dc.description.abstract	Background: Implantation of insulin-secreting cells has been trialed as a treatment for Type 1 diabetes mellitus; however, the host immunogenic response limits their effectiveness. Methodology: The authors developed a core-shell nanostructure of upconversion nanoparticle-mesoporous silica for controlled local delivery of an immunomodulatory agent, MCC950, using near-infrared light and validated it in in vitro models of fibrosis. Results: The individual components of the nanosystem did not affect the proliferation of insulin-secreting cells, unlike fibroblast proliferation (p < 0.01). The nanosystem is effective at releasing MCC950 and preventing fibroblast differentiation (p < 0.01), inflammation (IL-6 expression; p < 0.05) and monocyte adhesion (p < 0.01). Conclusion: This MCC950-loaded nanomedicine system could be used in the future together with insulin-secreting cell implants to increase their longevity as a curative treatment for Type 1 diabetes mellitus.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	FUTURE MEDICINE LTD
dc.relation	Juvenile Diabetes Foundation InternationalJDRF International: 1-INO-2020-914-A-N
dc.relation.ispartof	Nanomedicine (Lond)
dc.relation.isbasedon	10.2217/nnm-2022-0231
dc.rights	info:eu-repo/semantics/embargoedAccess
dc.subject	0306 Physical Chemistry (incl. Structural), 1004 Medical Biotechnology, 1007 Nanotechnology
dc.subject.classification	Nanoscience & Nanotechnology
dc.subject.classification	3206 Medical biotechnology
dc.subject.classification	4003 Biomedical engineering
dc.subject.classification	4018 Nanotechnology
dc.subject.mesh	Humans
dc.subject.mesh	Diabetes Mellitus, Type 1
dc.subject.mesh	Drug Delivery Systems
dc.subject.mesh	Nanoparticles
dc.subject.mesh	Nanostructures
dc.subject.mesh	Humans
dc.subject.mesh	Diabetes Mellitus, Type 1
dc.subject.mesh	Drug Delivery Systems
dc.subject.mesh	Nanostructures
dc.subject.mesh	Nanoparticles
dc.subject.mesh	Humans
dc.subject.mesh	Diabetes Mellitus, Type 1
dc.subject.mesh	Drug Delivery Systems
dc.subject.mesh	Nanoparticles
dc.subject.mesh	Nanostructures
dc.title	In vitro evaluation of a hybrid drug-delivery nanosystem for fibrosis prevention in cell therapy for Type 1 diabetes.
dc.type	Journal Article
utslib.citation.volume	18
utslib.location.activity	England
utslib.for	0306 Physical Chemistry (incl. Structural)
utslib.for	1004 Medical Biotechnology
utslib.for	1007 Nanotechnology
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	University of Technology Sydney/Faculty of Science
pubs.organisational-group	University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	University of Technology Sydney/Faculty of Science/School of Mathematical and Physical Sciences
pubs.organisational-group	University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	University of Technology Sydney/Strength - IBMD - Initiative for Biomedical Devices
utslib.copyright.status	open_access	*
utslib.copyright.embargo	2024-03-20T00:00:00+1000Z
dc.date.updated	2024-03-07T23:42:11Z
pubs.issue	1
pubs.publication-status	Published
pubs.volume	18
utslib.citation.issue	1

Abstract:

Background: Implantation of insulin-secreting cells has been trialed as a treatment for Type 1 diabetes mellitus; however, the host immunogenic response limits their effectiveness. Methodology: The authors developed a core-shell nanostructure of upconversion nanoparticle-mesoporous silica for controlled local delivery of an immunomodulatory agent, MCC950, using near-infrared light and validated it in in vitro models of fibrosis. Results: The individual components of the nanosystem did not affect the proliferation of insulin-secreting cells, unlike fibroblast proliferation (p < 0.01). The nanosystem is effective at releasing MCC950 and preventing fibroblast differentiation (p < 0.01), inflammation (IL-6 expression; p < 0.05) and monocyte adhesion (p < 0.01). Conclusion: This MCC950-loaded nanomedicine system could be used in the future together with insulin-secreting cell implants to increase their longevity as a curative treatment for Type 1 diabetes mellitus.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/176319